FABP4抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse liver tissue and Rat liver tissue lysates, Primary antibody: P06573(GLUD1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P06573(GLUD1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Fatty Acid-Binding Protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2. is a lipid chaperone protein primarily expressed in adipocytes and macrophages. It plays a critical role in lipid metabolism, inflammation, and cellular signaling by facilitating the transport of fatty acids and regulating their intracellular distribution. FABP4 is implicated in metabolic disorders such as obesity, insulin resistance, and atherosclerosis, as well as cancer progression and immune modulation. Its dysregulation is associated with pathological processes like adipose tissue dysfunction, chronic inflammation, and tumor microenvironment remodeling.

FABP4 antibodies are essential tools for detecting and quantifying this protein in research and diagnostic applications. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA) to study FABP4 expression patterns in tissues, cells, or biological fluids. These antibodies help elucidate FABP4's role in metabolic diseases, cancer metastasis, and inflammatory responses. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple epitopes, enhancing sensitivity in certain assays. Validation of FABP4 antibodies often includes knockout controls to confirm target specificity.

Recent studies highlight FABP4 as a potential therapeutic target or biomarker for metabolic syndromes and cancers, driving demand for reliable antibodies in drug development and mechanistic studies. Their applications extend to evaluating therapeutic interventions targeting FABP4 pathways in preclinical models.